Search clinical trials for: tremelimumab durvalumab

Total 775 results

Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Solid Malignancies

Canada
John L. Villano, MD, PhD

Active, not recruiting

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Tumor, Solid

United States
Yonsei University

Completed

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Metastatic Breast Cancer

Korea, Republic of
Samsung Medical Center

Active, not recruiting

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
Seoul National University Hospital

Unknown

Pulmonary sarcomatoid_MEDI4736+Treme

Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC

Korea, Republic of
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Metastatic Bladder Cancer | Non-Transitional Cell Carcinoma of the Urothelial Tract | Small Cell of the Bladder

United States
University of Erlangen-Nürnberg Medical School

Completed

Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Locally Advanced Head and Neck Squamous Cell Carcinoma

Germany
Centre Georges Francois Leclerc
AstraZeneca

Completed

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (MEDITREME)

Colorectal Cancer Metastatic

France
AstraZeneca

Active, not recruiting

Durvalumab and Tremelimumab for Pediatric Malignancies

Pediatric Cancer | Hematological Malignancies | Solid Tumor Pediatric

Spain, Italy, United States, United Kingdom, France, Netherlands, Germany
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
Italian Network for Tumor Biotherapy Foundation
AstraZeneca

Unknown

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Peritoneal Mesothelioma | Pleural Mesothelioma

Italy
AstraZeneca

Completed

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Advanced Malignancy

China
Immunocore Ltd
AstraZeneca

Completed

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Malignant Melanoma

United States
Yonsei University
National Cancer Center, Korea; Samsung Medical Center; AstraZeneca; Seoul National... and other collaborators

Unknown

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) (KGOG3046)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

Korea, Republic of
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Metastatic Anaplastic Thyroid Cancer

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Metastatic Colorectal Cancer

United States
Universitaire Ziekenhuizen KU Leuven
AstraZeneca; European Organisation for Research and Treatment of Cancer - EORTC and other collaborators

Active, not recruiting

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO)

Oral Cavity Squamous Cell Carcinoma

Belgium
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands
MedImmune LLC

Completed

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Canada
AIO-Studien-gGmbH
AstraZeneca

Withdrawn

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

NSCLC Stage IV

Germany
Yonsei University

Active, not recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Larynx | Stage II-IVB Operable HNSCC Oral Cavity | Hypopharynx | Oropharynx

Korea, Republic of
MedImmune LLC

Completed

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Diffuse Large B-Cell Lymphoma

United States, France, United Kingdom, Ireland
AstraZeneca

Completed

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Advanced Solid Tumors

Japan, Korea, Republic of, Taiwan
MedImmune LLC

Completed

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Germany, Spain, Canada, France, Korea, Republic of, Israel, Netherlands, United Kingdom
ARCAGY/ GINECO GROUP
AstraZeneca

Active, not recruiting

Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV)

Ovarian Cancer

France
NSABP Foundation Inc

Completed

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Colorectal Cancer Metastatic

United States
University of Cologne
AstraZeneca

Active, not recruiting

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE)

Esophageal Adenocarcinoma

Germany
AstraZeneca

Active, not recruiting

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

Hepatocellular Carcinoma

United States, Canada, Brazil, France, Italy, Russian Federation, Spain, Vietnam, Korea, Republic of, China, Germany, Ukraine, Japan, Hong Kong, Taiwan, India, Thailand
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
Centre Georges Francois Leclerc
AstraZeneca

Active, not recruiting

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR)

Immunotherapy

France
Samsung Medical Center

Unknown

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Enrico De Toni

Recruiting

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC)

Hepatocellular Carcinoma

Germany
Yonsei University
Samsung Medical Center; AstraZeneca; Seoul National University Hospital; Korean... and other collaborators

Recruiting

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Platinum-resistant Recurrent Ovarian Cancer

Korea, Republic of
Asan Medical Center
Seoul National University Bundang Hospital; Hallym University Medical Center

Completed

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Metastatic Gastric Cancer

Korea, Republic of
Nordic Society of Gynaecological Oncology - Clinical...
European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic...

Completed

Trial in Patients With Relapsed Ovarian Cancer

Ovarian Cancer

Norway, Finland, Denmark
Fondazione IRCCS Istituto Nazionale dei Tumori,...
AstraZeneca

Terminated

Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors (APACHE)

Germ Cell Tumor

Italy
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
MedImmune LLC

Completed

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma

Canada, United States, Taiwan, Korea, Republic of, Japan, Singapore
Baylor College of Medicine

Completed

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
MedImmune LLC

Terminated

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (MEDI6469)

Advanced Solid Tumors | Aggressive B-cell Lymphomas

United States
Yale University
AstraZeneca

Withdrawn

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Malignant Melanoma
Yale University

Completed

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Breast Neoplasms

United States
AstraZeneca

Recruiting

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma (TREMENDOUS)

Hepatocellular Carcinoma

China
Gruppo Oncologico del Nord-Ovest

Recruiting

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY)

Gastric Cancer | Microsatellite Instability

Italy
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

Canada
Grupo Espanol de Tumores Neuroendocrinos
MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)

Metastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular Carcinoma

Spain
Centre hospitalier de l'Université de Montréal...
AstraZeneca

Active, not recruiting

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma

Canada
AIO-Studien-gGmbH
AstraZeneca

Completed

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma (MEDISARC)

Recurrent Adult Soft Tissue Sarcoma | Metastatic Adult Soft Tissue Sarcoma

Germany
University College, London
AstraZeneca; Cancer Research UK; Kidney Cancer UK

Recruiting

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)

Renal Cell Carcinoma

United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Endometrial Cancer | Endometrial Carcinoma | Endometrial Carcinosarcoma | Endometrial Cancer Recurrent | Endometrial Carcinoma, Recurrent

United States

Search clinical trials for: tremelimumab durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations